Trial to Compare the Effects of Either Telmisartan (40-80 mg PO Once Daily) or Ramipril (5-10 mg PO Once Daily) on Renal Endothelial Dysfunction in Hypertensive Patients With Type 2 Diabetes

NCT00240422 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

96

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Type 2
Hypertension

Interventions

DRUG: Telmisartan
DRUG: Ramipril

Sponsor

Boehringer Ingelheim